PriceTargets.com logo

Trevi Therapeutics - TRVI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.10
  • Forecasted Upside: 93.58%
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 2 Strong Buy Ratings
$10.90 As of 02/2/2026 12:26 PM ET
▲ +0.43 (4.11%)

This chart shows the closing price for TRVI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Trevi Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TRVI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TRVI

Analyst Price Target is $21.10
▲ +93.58% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Trevi Therapeutics in the last 3 months. The average price target is $21.10, with a high forecast of $27.00 and a low forecast of $16.00. The average price target represents a 93.58% upside from the last price of $10.90.

This chart shows the closing price for TRVI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 11 contributing investment analysts is to buy stock in Trevi Therapeutics. This rating has held steady since November 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/10/2024
  • 2 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/8/2024
  • 2 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2025
  • 3 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/7/2025
  • 3 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/3/2025
  • 2 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/2/2026
  • 2 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/1/2026

Latest Recommendations

  • 2 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/9/2026HC WainwrightReiterated RatingBuy ➝ Buy$21.00
1/8/2026D. Boral CapitalReiterated RatingBuy ➝ Buy$19.00
12/19/2025Stifel NicolausBoost TargetBuy ➝ Buy$15.00 ➝ $18.00
11/19/2025Leerink PartnersBoost TargetOutperform ➝ Outperform$13.00 ➝ $16.00
11/17/2025B. RileyUpgradeStrong-Buy
11/14/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$18.00 ➝ $19.00
11/14/2025OppenheimerBoost TargetOutperform ➝ Outperform$23.00 ➝ $24.00
11/14/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$19.00
11/13/2025Leerink PartnersInitiated CoverageOutperform$13.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/21/2025Morgan StanleyInitiated CoverageOverweight$18.00
8/8/2025Raymond James FinancialLower TargetStrong-Buy ➝ Strong-Buy$29.00 ➝ $27.00
8/8/2025Needham & Company LLCLower TargetBuy ➝ Buy$24.00 ➝ $22.00
7/1/2025Cantor FitzgeraldInitiated CoverageOverweight$25.00
6/2/2025OppenheimerReiterated RatingOutperform ➝ Outperform
6/2/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$21.00
5/28/2025HC WainwrightInitiated CoverageBuy ➝ Buy$21.00
5/20/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
4/8/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
3/19/2025B. RileyReiterated RatingBuy ➝ Buy$11.00 ➝ $20.00
3/19/2025HC WainwrightReiterated RatingBuy ➝ Buy$12.50 ➝ $12.50
3/19/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00
3/19/2025Needham & Company LLCLower TargetBuy ➝ Buy$25.00 ➝ $24.00
3/11/2025OppenheimerBoost TargetOutperform ➝ Outperform$12.00 ➝ $20.00
3/10/2025HC WainwrightBoost TargetBuy ➝ Buy$7.50 ➝ $12.50
3/10/2025Raymond James FinancialUpgradeOutperform ➝ Strong-Buy$9.00 ➝ $29.00
3/10/2025Needham & Company LLCBoost TargetBuy ➝ Buy$8.00 ➝ $25.00
3/7/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00
2/24/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00
1/8/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00
12/12/2024HC WainwrightBoost TargetBuy ➝ Buy$6.00 ➝ $7.50
12/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
12/12/2024D. Boral CapitalReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00
12/4/2024HC WainwrightReiterated RatingBuy ➝ Buy
12/4/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
12/4/2024D. Boral CapitalReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00
11/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
10/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
10/7/2024B. RileyReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
10/4/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
9/9/2024Leerink PartnersUpgradeStrong-Buy
9/9/2024Leerink PartnersInitiated CoverageOutperform$6.00 ➝ $7.00
8/30/2024HC WainwrightInitiated CoverageBuy$6.00
8/30/2024Raymond James FinancialInitiated CoverageOutperform$9.00
8/19/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
6/13/2024Rodman & RenshawInitiated CoverageBuy$7.00
5/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$8.00
4/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$8.00
3/21/2024OppenheimerReiterated RatingOutperform ➝ Outperform$9.00
3/21/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$8.00
8/11/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$8.00
4/12/2023B. RileyInitiated CoverageBuy$6.00
3/17/2023Needham & Company LLCReiterated RatingBuy$8.00
3/14/2023JonestradingInitiated CoverageBuy$7.00
11/22/2022Leerink PartnersInitiated CoverageOutperform$6.00
11/17/2022OppenheimerLower Target$9.00
11/11/2022Needham & Company LLCLower TargetBuy$10.00 ➝ $8.00
7/4/2022OppenheimerBoost Target$12.00
6/29/2022Needham & Company LLCBoost TargetBuy$8.00 ➝ $10.00
5/24/2022OppenheimerInitiated CoverageOutperform$10.00
3/29/2022AegisInitiated CoverageBuy$10.00
11/11/2021Needham & Company LLCLower TargetBuy$10.00 ➝ $8.00
8/13/2021Needham & Company LLCLower TargetBuy$12.00 ➝ $10.00
(Data available from 2/2/2021 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 19 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/5/2025
  • 17 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 13 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025
  • 10 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026

Current Sentiment

  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Trevi Therapeutics logo
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Read More

Today's Range

Now: $10.90
Low: $10.42
High: $10.96

50 Day Range

MA: $12.03
Low: $9.99
High: $14.17

52 Week Range

Now: $10.90
Low: $3.77
High: $14.39

Volume

230,442 shs

Average Volume

1,457,757 shs

Market Capitalization

$1.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Trevi Therapeutics?

The following Wall Street research analysts have issued reports on Trevi Therapeutics in the last year: B. Riley, Cantor Fitzgerald, D. Boral Capital, HC Wainwright, Leerink Partners, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings, Inc., Raymond James Financial, Inc., Stifel Nicolaus, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for TRVI.

What is the current price target for Trevi Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Trevi Therapeutics in the last year. Their average twelve-month price target is $21.10, suggesting a possible upside of 93.6%. Raymond James Financial, Inc. has the highest price target set, predicting TRVI will reach $27.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $16.00 for Trevi Therapeutics in the next year.
View the latest price targets for TRVI.

What is the current consensus analyst rating for Trevi Therapeutics?

Trevi Therapeutics currently has 1 sell rating, 8 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TRVI will outperform the market and that investors should add to their positions of Trevi Therapeutics.
View the latest ratings for TRVI.

What other companies compete with Trevi Therapeutics?

Other companies that are similar to Trevi Therapeutics include Protagonist Therapeutics, Kymera Therapeutics, Crinetics Pharmaceuticals, Mirum Pharmaceuticals and TG Therapeutics. Learn More about companies similar to Trevi Therapeutics.

How do I contact Trevi Therapeutics' investor relations team?

Trevi Therapeutics' physical mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The company's listed phone number is (203) 304-2499 and its investor relations email address is [email protected]. The official website for Trevi Therapeutics is www.trevitherapeutics.com. Learn More about contacing Trevi Therapeutics investor relations.